Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.2 to v3.6.3, reflecting a new build of the page.
    Difference
    0.0%
    Check dated 2026-07-04T13:25:56.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page's revision version was updated from v3.6.0 to v3.6.2, signaling a subsequent update to the page's content or presentation.
    Difference
    0.0%
    Check dated 2026-06-27T07:38:12.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page now indicates no further participant recruitment and introduces new user-help sections for reading the study record and joining, along with a revision label; a formatting change to the Intervention/Treatment heading is also applied.
    Difference
    0.4%
    Check dated 2026-06-13T04:32:55.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.4 to v3.5.5, indicating a new version of the page content. This appears to be a metadata/software update that does not change the study details, eligibility, or results.
    Difference
    0.0%
    Check dated 2026-06-05T22:02:21.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.5.3 to v3.5.4. This indicates a new version of the page without changes to the study details.
    Difference
    0.0%
    Check dated 2026-05-15T15:01:03.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    A Publications section was added, listing a PubMed citation for Subcutaneous ocrelizumab in multiple sclerosis and noting that these publications are automatically filled from PubMed.
    Difference
    0.2%
    Check dated 2026-05-08T11:45:05.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.